CoChat
Sign Up
Cited by 82

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Altered Rho GTPase Signaling Pathways in Breast Cancer Cells

Burbelo, Peter, Wellstein, Anton, Pestell, Richard G.·2004·Breast Cancer Research and Treatment
DOI 10.1023/b:brea.0000018422.02237.f9
Open this paper in CoChat — free account

Abstract

The Rho family of GTPases have emerged as key players in regulating a diverse set of biological activities including actin organization, focal complex/adhesion assembly, cell motility, cell polarity, gene transcription and cell-cycle progression. Some Rho GTPases and their signaling components are overexpressed and/or are hyperactive in breast cancer and recent studies have shown a requirement for Rho GTPases in breast cancer cell metastasis in vivo. Herein we describe the contribution of Rho GTPase to the malignant phenotype of breast cancer cells and the role of these pathways as potential targets for breast cancer therapy. Rho GTPases promote cell-cycle progression through cyclin D1, and cyclin D1 in turn reduces cellular adhesion and promotes migration, an example of 'inside-out' signaling by cyclin D1. As cyclin D1 overexpression correlates with metastatic cancer, the 'inside-out' signaling function of cyclin D1 to promote cell migration may represent a useful new therapeutic target.

Overview

Integrity signals

Registry

Crossref · 10.1023/b:brea.0000018422.02237.f9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 45

  1. Hall A: Rho GTPases and the actin cytoskeleton. Science 279: 509–514, 1998 · DOI
  2. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A: The small GTP-binding protein rac regulates growth factorinduced membrane ruffling. Cell 70: 401–410, 1992 · DOI
  3. Ridley AJ, Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389–399, 1992 · DOI
  4. Bishop AL, Hall A: Rho GTPases and their effector proteins. Biochem J 348(Pt 2): 241–255, 2000 · DOI · Paper page
  5. Olofsson B: Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal 11: 545–554, 1999 · DOI
  6. Whitehead IP, Campbell S, Rossman KL, Der CJ: Dbl family proteins. Biochim Biophys Acta 1332: F1-F23, 1997
  7. Zheng Y: Dbl family guanine nucleotide exchange factors. Trends Biochem Sci 26: 724–732, 2001 · DOI · Paper page
  8. Peck J, Douglas IV G, Wu CH, Burbelo PD: Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships. FEBS Lett 528: 27–34, 2002 · DOI
  9. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B: Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87: 635–644, 2002 · DOI
  10. Fritz G, Just I, Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682–687, 1999 · DOI
  11. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD: A novel putative low-affinity insulin-like growth factorbinding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5: 2511–2519, 1999
  12. Kleer CG, van Golen KL, Zhang Y, Wu ZF, Rubin MA, Merajver SD: Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160: 579–584, 2002 · DOI · Paper page
  13. Clark EA, Golub TR, Lander ES, Hynes RO: Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406: 532–535, 2000 · DOI
  14. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E: Rac1 in human breast cancer; overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19: 3013–3020, 2000 · DOI · Paper page
  15. Mira JP, Benard V, Groffen J, Sanders LC, Knaus UG: Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway. Proc Natl Acad Sci USA 97: 185–189, 2000 · DOI
  16. Evers EE, Zondag GCM, Malliri A, Price LS, ten Klooster J-P, van der Kammen RA, Collard JG: Rho family of proteins in cell adhesion and cell migration. Eur J Cancer 36: 1269–1274, 2000 · DOI
  17. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV: Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 390: 632–636, 1997 · DOI
  18. van Golen KL, Bao LW, Pan Q, Miller FR, Wu ZF, Merajver SD: Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metast 19: 301–311, 2002 · DOI
  19. van Golen KL, Wu ZF, Qiao XT, Bao L, Merajver SD: RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2: 418–425, 2000 · DOI
  20. Bouzahzah B, Albanese C, Ahmed F, Pixley F, Lisanti MP, Segall JD, Condeelis J, Joyce D, Minden A, Der CJ, Chan A, Symons M, Pestell RG: Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways. Mol Med 7: 816–830, 2001 · DOI
  21. Olson MF, Ashworth A, Hall A: An essential role for Rho, Rac and Cdc42 GTPases in cell cycle progression through G1. Science 269: 1270–1272, 1995 · DOI
  22. Qiu R-G, Chen J, McCormick F, Symons M: A role for Rho in Ras transformation. Proc Natl Acad Sci USA 92: 11781–11785, 1995 · DOI · Paper page
  23. Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, Der CJ: Rac regulation of transformation, gene expression and actin organisation by multiple, PAKindependent pathways. Mol Cell Biol 17: 1324–1335, 1997 · DOI
  24. Westwick JK, Lee RJ, Lambert QT, Symons M, Pestell RG, Der CJ, Whitehead IP: Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. J Biol Chem 273: 16739–16747, 1998 · DOI
  25. Whitehead IP, Lambert QT, Glaven JA, Abe K, Rossman KL, Mahon GM, Trzaskos JM, Kay R, Campbell SL, Der CJ: Dependence of Dbl and Dbs transformation on MEK and NF-κ activation. Mol Cell Biol 19: 7759–7770, 1999 · DOI
  26. Liberto M, Cobrinik D, Minden A: Rho regulates p21(CIP1), cyclin D1, and checkpoint control inmammary epithelial cells. Oncogene 21: 1590–1599, 2002 · DOI
  27. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GKI, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG: Cyclin D1 is required for transformation by activated Neu and is induced through an E2Fdependent signaling pathway. Mol Cell Biol 20: 672–683, 2000 · DOI
  28. Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG: Integration of Rac-dependent regulation of cyclin D1 transcription through an NF-κ-dependent pathway. J Biol Chem 274: 25245–25249, 1999 · DOI
  29. Albanese C, Jarrett CR, Joyce D, Hughes J, Wu K, D'Amico M, Fu M, Sakamaki T, Ben Ze'ev A, Lamberti C, Lin K-M, Gaynor RB, Byers SW, Pestell RG: IKKá activates Tcf signaling and cyclin D1 gene expression through phosphorylation of β-catenin. Mol Cell Biol (in press)
  30. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS: NF-κ controls cell growth and differentiation through the transcriptional regulation of cyclin D1. Mol Cell Biol 19: 5785–5799, 1999 · DOI
  31. Salh B, Marotta A, Wagey R, Sayed M, Pelech S: Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 98: 148–154, 2002 · DOI
  32. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J, Hung MC, Kumar R: Regulatable expression of p21-activated kinase-1 promotes anchorageindependent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275: 36238–36244, 2000 · DOI
  33. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R: Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273: 28238–28246, 1998 · DOI
  34. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R: Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 275: 12041–12050, 2000 · DOI
  35. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S: An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5: 221–225, 1999 · DOI
  36. Yoshioka K, Nakamori S, Itoh K: Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 59: 2004–2010, 1999
  37. Nguyen QD, Faivre S, Bruyneel E, Rivat C, Seto M, Endo T, Mareel M, Emami S, Gespach C: RhoA-and RhoDdependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion. Faseb J 16: 565–576, 2002 · DOI
  38. Sahai E, Marshall CJ: ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol 4: 408–415, 2002 · DOI
  39. Prendergast GC: ‘Actin’ up: RhoB in cancer and apoptosis. Nat Rev Cancer 1: 162–168, 2001 · DOI
  40. Du W, Prendergast GC: Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res 59: 5492–5496, 1999
  41. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C: Cerivastatin, an inhibitor of HMGCoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139–1148, 2001 · DOI
  42. Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, Suzuki-Takahashi I, Jorissen RN, Burgess AW, Nishimura S, Wood J, Maruta H: The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 8: 328–336, 2002 · DOI
  43. Hendrik Gille H, Downward J: Multiple ras effector pathways contribute to G1 cell cycle progression. J Biol Chem 274: 22033–22040, 1999 · DOI
  44. Holnthoner W, Pillinger M, Groger M, Wolff K, Ashton AW, Albanese C, Neumeister P, Pestell RG, Petzelbauer P: Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells. J Biol Chem 277: 45847–45853, 2002 · DOI
  45. Neumeister P, Pixley FJ, Xiong Y, Xie H, Wu K, Ashton A, Cammer M, Chan A, Symons M, Stanley ER, Pestell RG: Cyclin D1 governs adhesion and motility of macrophages. Mol Biol Cell 14: 2005–2015, 2003 · DOI

Cited by

Metadata

Authors
Burbelo, P., Wellstein, A., & Pestell, R. G.
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
2004-03
Volume
84
Issue
1
Pages
43-48
ISSN
  • 0167-6806
  • 1573-7217
DOI
10.1023/b:brea.0000018422.02237.f9
Cited by
82
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review